1	Direct	B
2	current	B
3	polarography	B
4	and	B
5	differential	B
6	pulse	B
7	polarographic	B
8	methods	B
9	have	B
10	been	B
11	developed	B
12	for	B
13	the	B
14	qualitative	B
15	as	B
16	well	B
17	as	B
18	quantitative	B
19	analysis	B
20	of	B
21	vitamin	B
22	B1	B
23	,	B
24	B2	B
25	and	B
26	B6	B
27	.	B

1	Fluorimetric	B
2	determination	B
3	of	B
4	methylmercury	B
5	as	B
6	an	B
7	ion	B
8	-	B
9	association	B
10	complex	B
11	with	B
12	rhodamine	B
13	B	B
14	in	B
15	the	B
16	presence	B
17	of	B
18	iodide	B
19	.	B

1	The	B
2	corresponding	B
3	genotype	B
4	was	B
5	determined	B
6	with	B
7	a	B
8	restriction	B
9	enzyme	B
10	-	B
11	based	B
12	assay	B
13	.	B

1	Patients	B
2	were	B
3	divided	B
4	into	B
5	two	B
6	group	B
7	;	B
8	Control	B
9	group	B
10	A	B
11	in	B
12	which	B
13	a	B
14	hot	B
15	-	B
16	water	B
17	circulating	B
18	system	B
19	was	B
20	used	B
21	and	B
22	group	B
23	B	B
24	in	B
25	which	B
26	a	B
27	transtracheal	B
28	heating	B
29	and	B
30	humidification	B
31	system	B
32	by	B
33	ANAMED	B
34	HUMITUBE	B
35	was	B
36	used	B
37	,	B
38	during	B
39	gastric	B
40	cancer	B
41	operation	B
42	.	B

1	Mental	B
2	rotation	B
3	of	B
4	paired	B
5	figures	B
6	engendered	B
7	activation	B
8	in	B
9	the	B
10	left	B
11	superior	B
12	parietal	B
13	lobule	B
14	and	B
15	the	B
16	right	B
17	frontal	B
18	medial	B
19	gyrus	B
20	.	B

1	Here	B
2	we	B
3	demonstrate	B
4	that	B
5	the	B
6	Ras	B
7	-	B
8	activated	B
9	Raf	B
10	-	B
11	MEK	B
12	-	B
13	extracellular	B
14	signal	B
15	-	B
16	regulated	B
17	kinase	B
18	(	B
19	ERK	B
20	)	B
21	signaling	B
22	pathway	B
23	can	B
24	specifically	B
25	control	B
26	the	B
27	expression	B
28	of	B
29	individual	B
30	integrin	B
31	subunits	B
32	in	B
33	a	B
34	variety	B
35	of	B
36	human	B
37	and	B
38	mouse	B
39	cell	B
40	lines	B
41	.	B

1	These	B
2	TxRE	B
3	contain	B
4	cyclic	B
5	AMP	B
6	-	B
7	responsive	B
8	elements	B
9	(	B
10	CRE	B
11	),	B
12	but	B
13	,	B
14	remarkably	B
15	,	B
16	the	B
17	"	B
18	TGACGTCA	B
19	"	B
20	consensus	B
21	is	B
22	never	B
23	strictly	B
24	conserved	B
25	in	B
26	any	B
27	viral	B
28	strain	B
29	(	B
30	e	B
31	.	B
32	g	B
33	.,	B
34	AGACGTCA	B
35	,	B
36	TGACGGCA	B
37	,	B
38	TGACCTCA	B
39	).	B

1	The	B
2	hatcher	B
3	incubators	B
4	of	B
5	both	B
6	companies	B
7	were	B
8	also	B
9	persistently	B
10	contaminated	B
11	with	B
12	Salmonella	B
13	livingstone	B
14	and	B
15	Salmonella	B
16	thomasville	B
17	in	B
18	company	B
19	A	B
20	and	B
21	with	B
22	Salmonella	B
23	senftenberg	B
24	in	B
25	company	B
26	B	B
27	.	B

1	Binding	B
2	of	B
3	cell	B
4	type	B
5	-	B
6	specific	B
7	nuclear	B
8	proteins	B
9	to	B
10	the	B
11	5	B
12	'-	B
13	flanking	B
14	region	B
15	of	B
16	maize	B
17	C4	B
18	phosphoenolpyruvate	B
19	carboxylase	B
20	gene	B
21	confers	B
22	its	B
23	differential	B
24	transcription	B
25	in	B
26	mesophyll	B
27	cells	B
28	.	B

1	Susceptibility	B
2	to	B
3	ischemia	B
4	-	B
5	induced	B
6	arrhythmias	B
7	was	B
8	lower	B
9	in	B
10	1	B
11	-	B
12	week	B
13	diabetics	B
14	:	B
15	only	B
16	42	B
17	%	B
18	of	B
19	diabetic	B
20	hearts	B
21	exhibited	B
22	ventricular	B
23	tachycardia	B
24	(	B
25	VT	B
26	)	B
27	and	B
28	16	B
29	%	B
30	had	B
31	short	B
32	episodes	B
33	of	B
34	ventricular	B
35	fibrillation	B
36	(	B
37	VF	B
38	)	B
39	as	B
40	compared	B
41	to	B
42	VT	B
43	100	B
44	%	B
45	and	B
46	VF	B
47	70	B
48	%	B
49	(	B
50	including	B
51	sustained	B
52	VF	B
53	36	B
54	%)	B
55	in	B
56	the	B
57	non	B
58	-	B
59	diabetics	B
60	(	B
61	P	B
62	<	B
63	0	B
64	.	B
65	05	B
66	).	B

1	CONCLUSIONS	B
2	:	B
3	The	B
4	methodology	B
5	of	B
6	LHR	B
7	measurement	B
8	significantly	B
9	influences	B
10	the	B
11	clinical	B
12	contribution	B
13	of	B
14	Tl	B
15	-	B
16	201	B
17	lung	B
18	uptake	B
19	evaluation	B
20	.	B

1	The	B
2	authors	B
3	made	B
4	an	B
5	analysis	B
6	of	B
7	social	B
8	-	B
9	economical	B
10	conditions	B
11	limiting	B
12	the	B
13	possibilities	B
14	of	B
15	rendering	B
16	cardiosurgical	B
17	care	B
18	to	B
19	children	B
20	.	B

1	METHODS	B
2	:	B
3	Experiments	B
4	testing	B
5	the	B
6	new	B
7	catheter	B
8	and	B
9	comparing	B
10	it	B
11	to	B
12	the	B
13	existing	B
14	catheter	B
15	included	B
16	:	B
17	(	B
18	1	B
19	)	B
20	measurement	B
21	of	B
22	the	B
23	laser	B
24	output	B
25	beam	B
26	sizes	B
27	and	B
28	divergences	B
29	;	B
30	(	B
31	2	B
32	)	B
33	evaluation	B
34	of	B
35	particulate	B
36	matter	B
37	generation	B
38	during	B
39	ablation	B
40	of	B
41	atherosclerotic	B
42	tissue	B
43	;	B
44	(	B
45	3	B
46	)	B
47	measurement	B
48	of	B
49	ablation	B
50	hole	B
51	sizes	B
52	and	B
53	tissue	B
54	penetration	B
55	rates	B
56	;	B
57	(	B
58	4	B
59	)	B
60	histopathologic	B
61	examination	B
62	of	B
63	laser	B
64	-	B
65	induced	B
66	in	B
67	vivo	B
68	vessel	B
69	wall	B
70	injury	B
71	.	B

1	The	B
2	reproductive	B
3	effects	B
4	of	B
5	the	B
6	administration	B
7	of	B
8	4	B
9	-	B
10	chloro	B
11	-	B
12	2	B
13	-	B
14	methylphenoxyacetic	B
15	acid	B
16	(	B
17	MCPA	B
18	)	B
19	to	B
20	rats	B
21	were	B
22	evaluated	B
23	through	B
24	two	B
25	generations	B
26	,	B
27	from	B
28	prior	B
29	to	B
30	mating	B
31	,	B
32	throughout	B
33	mating	B
34	,	B
35	to	B
36	gestation	B
37	and	B
38	lactation	B
39	.	B

1	Here	B
2	we	B
3	suggest	B
4	that	B
5	uvrA	B
6	and	B
7	the	B
8	nucleotide	B
9	excision	B
10	repair	B
11	pathway	B
12	are	B
13	involved	B
14	in	B
15	the	B
16	repair	B
17	of	B
18	acid	B
19	-	B
20	induced	B
21	DNA	B
22	damage	B
23	and	B
24	are	B
25	associated	B
26	with	B
27	successful	B
28	adaptation	B
29	of	B
30	S	B
31	.	B
32	mutans	B
33	to	B
34	low	B
35	pH	B
36	.	B

1	The	B
2	improved	B
3	CSF	B
4	outflow	B
5	conductance	B
6	may	B
7	increase	B
8	the	B
9	intracranial	B
10	compliance	B
11	and	B
12	thereby	B
13	dampen	B
14	a	B
15	pathological	B
16	ICP	B
17	waveform	B
18	.	B

1	These	B
2	studies	B
3	demonstrate	B
4	that	B
5	site	B
6	-	B
7	specific	B
8	recognition	B
9	of	B
10	the	B
11	bxd	B
12	PRE	B
13	by	B
14	d	B
15	(	B
16	GA	B
17	)(	B
18	n	B
19	)	B
20	repeat	B
21	binding	B
22	activities	B
23	mediates	B
24	PcG	B
25	-	B
26	dependent	B
27	silencing	B
28	.	B

1	The	B
2	gonadotrope	B
3	-	B
4	specific	B
5	and	B
6	regulated	B
7	expression	B
8	of	B
9	the	B
10	GnRH	B
11	receptor	B
12	(	B
13	GnRH	B
14	-	B
15	R	B
16	)	B
17	gene	B
18	is	B
19	dependent	B
20	on	B
21	multiple	B
22	transcription	B
23	factors	B
24	that	B
25	interact	B
26	with	B
27	the	B
28	noncanonical	B
29	GnRH	B
30	-	B
31	R	B
32	activating	B
33	sequence	B
34	(	B
35	GRAS	B
36	),	B
37	the	B
38	activator	B
39	protein	B
40	-	B
41	1	B
42	(	B
43	AP	B
44	-	B
45	1	B
46	)	B
47	element	B
48	,	B
49	and	B
50	the	B
51	steroidogenic	B
52	factor	B
53	-	B
54	1	B
55	(	B
56	SF	B
57	-	B
58	1	B
59	)	B
60	binding	B
61	site	B
62	.	B

1	Before	B
2	PO3	B
3	administration	B
4	,	B
5	more	B
6	than	B
7	half	B
8	(	B
9	57	B
10	.	B
11	4	B
12	%)	B
13	of	B
14	the	B
15	patients	B
16	received	B
17	only	B
18	1	B
19	or	B
20	2	B
21	antituberculous	B
22	drugs	B
23	(	B
24	ethambutole	B
25	and	B
26	ethionamide	B
27	or	B
28	ethambutole	B
29	and	B
30	oprofloxacin	B
31	).	B

1	Using	B
2	the	B
3	presented	B
4	categorical	B
5	structure	B
6	as	B
7	domain	B
8	model	B
9	a	B
10	prototype	B
11	DSS	B
12	for	B
13	dipslide	B
14	urine	B
15	cultures	B
16	has	B
17	been	B
18	developed	B
19	.	B

1	Conclusion	B
2	:	B
3	The	B
4	Lp	B
5	(	B
6	a	B
7	)	B
8	levels	B
9	in	B
10	these	B
11	children	B
12	were	B
13	the	B
14	lower	B
15	ever	B
16	reported	B
17	.	B

1	Foxp1	B
2	and	B
3	Foxp2	B
4	are	B
5	expressed	B
6	at	B
7	high	B
8	levels	B
9	in	B
10	the	B
11	lung	B
12	as	B
13	early	B
14	as	B
15	E12	B
16	.	B
17	5	B
18	of	B
19	mouse	B
20	development	B
21	with	B
22	Foxp2	B
23	expression	B
24	restricted	B
25	to	B
26	the	B
27	airway	B
28	epithelium	B
29	.	B

1	Audiological	B
2	findings	B
3	in	B
4	pregnancy	B
5	.	B

1	Children	B
2	who	B
3	developed	B
4	lower	B
5	respiratory	B
6	tract	B
7	infections	B
8	or	B
9	PCP	B
10	had	B
11	increased	B
12	rates	B
13	of	B
14	decline	B
15	of	B
16	CD4	B
17	cell	B
18	counts	B
19	during	B
20	the	B
21	first	B
22	6	B
23	months	B
24	of	B
25	life	B
26	.	B

1	A	B
2	randomized	B
3	mix	B
4	of	B
5	180	B
6	sections	B
7	(	B
8	10	B
9	samples	B
10	x	B
11	3	B
12	tissues	B
13	x	B
14	3	B
15	stains	B
16	x	B
17	2	B
18	)	B
19	gave	B
20	90	B
21	matched	B
22	pairs	B
23	.	B

1	Sural	B
2	nerve	B
3	biopsy	B
4	showed	B
5	mild	B
6	thickening	B
7	of	B
8	the	B
9	perineurium	B
10	,	B
11	vascular	B
12	alterations	B
13	with	B
14	inflammatory	B
15	cell	B
16	infiltration	B
17	in	B
18	the	B
19	perineurium	B
20	,	B
21	and	B
22	remarkable	B
23	loss	B
24	of	B
25	large	B
26	and	B
27	small	B
28	myelinated	B
29	fibers	B
30	.	B

1	OBJECTIVES	B
2	:	B
3	The	B
4	objective	B
5	of	B
6	this	B
7	review	B
8	was	B
9	to	B
10	assess	B
11	the	B
12	effects	B
13	of	B
14	prophylactic	B
15	prostaglandin	B
16	use	B
17	in	B
18	the	B
19	third	B
20	stage	B
21	of	B
22	labour	B
23	.	B

1	Testing	B
2	was	B
3	associated	B
4	with	B
5	a	B
6	history	B
7	of	B
8	nonsexual	B
9	risk	B
10	behavior	B
11	,	B
12	increased	B
13	knowledge	B
14	of	B
15	the	B
16	hepatitis	B
17	C	B
18	virus	B
19	,	B
20	and	B
21	healthcare	B
22	provider	B
23	communication	B
24	.	B

1	Cytomegalovirus	B
2	,	B
3	Chlamydia	B
4	pneumoniae	B
5	,	B
6	and	B
7	Helicobacter	B
8	pylori	B
9	IgG	B
10	antibodies	B
11	and	B
12	restenosis	B
13	after	B
14	stent	B
15	implantation	B
16	:	B
17	an	B
18	angiographic	B
19	and	B
20	intravascular	B
21	ultrasound	B
22	study	B
23	.	B

1	A	B
2	5	B
3	-	B
4	month	B
5	-	B
6	old	B
7	infant	B
8	with	B
9	persistent	B
10	congenital	B
11	stridor	B
12	and	B
13	acute	B
14	respiratory	B
15	distress	B
16	is	B
17	presented	B
18	.	B

1	OBJECTIVE	B
2	:	B
3	To	B
4	determine	B
5	whether	B
6	RSTD	B
7	predicts	B
8	coronary	B
9	anatomy	B
10	during	B
11	acute	B
12	coronary	B
13	occlusion	B
14	.	B

1	Even	B
2	if	B
3	the	B
4	electrocardiographic	B
5	signs	B
6	are	B
7	subdued	B
8	,	B
9	the	B
10	underlying	B
11	blockade	B
12	of	B
13	I	B
14	(	B
15	Kr	B
16	)	B
17	current	B
18	may	B
19	precipitate	B
20	the	B
21	occurrence	B
22	of	B
23	arrhythmia	B
24	.	B

1	Acetoin	B
2	can	B
3	be	B
4	reused	B
5	by	B
6	the	B
7	bacteria	B
8	during	B
9	stationary	B
10	phase	B
11	when	B
12	other	B
13	carbon	B
14	sources	B
15	have	B
16	been	B
17	depleted	B
18	.	B

1	Analysis	B
2	of	B
3	the	B
4	promoter	B
5	sequence	B
6	revealed	B
7	the	B
8	presence	B
9	of	B
10	a	B
11	major	B
12	transcriptional	B
13	start	B
14	site	B
15	,	B
16	a	B
17	canonical	B
18	TATA	B
19	box	B
20	and	B
21	putative	B
22	cis	B
23	regulatory	B
24	elements	B
25	for	B
26	pituitary	B
27	specific	B
28	expression	B
29	as	B
30	well	B
31	as	B
32	an	B
33	E	B
34	-	B
35	responsive	B
36	element	B
37	.	B

1	IL	B
2	-	B
3	1beta	B
4	was	B
5	significantly	B
6	higher	B
7	in	B
8	endometrioma	B
9	than	B
10	in	B
11	lesions	B
12	of	B
13	other	B
14	localizations	B
15	.	B

1	An	B
2	economic	B
3	analysis	B
4	using	B
5	West	B
6	of	B
7	Scotland	B
8	Coronary	B
9	Prevention	B
10	Study	B
11	(	B
12	WOSCOPS	B
13	)	B
14	findings	B
15	indicates	B
16	that	B
17	statin	B
18	treatment	B
19	would	B
20	have	B
21	prevented	B
22	318	B
23	events	B
24	per	B
25	10	B
26	,	B
27	000	B
28	patients	B
29	in	B
30	a	B
31	population	B
32	similar	B
33	to	B
34	that	B
35	in	B
36	WOSCOPS	B
37	(	B
38	average	B
39	1	B
40	.	B
41	5	B
42	%	B
43	annual	B
44	risk	B
45	of	B
46	a	B
47	cardiovascular	B
48	event	B
49	)	B
50	at	B
51	a	B
52	discounted	B
53	cost	B
54	per	B
55	life	B
56	-	B
57	year	B
58	gained	B
59	of	B
60	20	B
61	,	B
62	375	B
63	pounds	B
64	($	B
65	31	B
66	,	B
67	818	B
68	).	B

1	Hydrogels	B
2	for	B
3	tissue	B
4	engineering	B
5	.	B

1	No	B
2	mutation	B
3	of	B
4	the	B
5	NRL	B
6	gene	B
7	was	B
8	found	B
9	in	B
10	any	B
11	of	B
12	the	B
13	two	B
14	families	B
15	.	B

1	However	B
2	,	B
3	most	B
4	produced	B
5	significant	B
6	alteration	B
7	of	B
8	small	B
9	intestinal	B
10	permeability	B
11	.	B

1	Our	B
2	results	B
3	show	B
4	that	B
5	CVN	B
6	specifically	B
7	recognizes	B
8	with	B
9	nanomolar	B
10	affinity	B
11	Man	B
12	(	B
13	9	B
14	)	B
15	GlcNAc	B
16	(	B
17	2	B
18	)	B
19	and	B
20	the	B
21	D1D3	B
22	isomer	B
23	of	B
24	Man	B
25	(	B
26	8	B
27	)	B
28	GlcNAc	B
29	(	B
30	2	B
31	).	B

1	Saccharomyces	B
2	cerevisiae	B
3	activates	B
4	a	B
5	regulatory	B
6	network	B
7	called	B
8	"	B
9	general	B
10	control	B
11	"	B
12	that	B
13	provides	B
14	the	B
15	cell	B
16	with	B
17	sufficient	B
18	amounts	B
19	of	B
20	protein	B
21	precursors	B
22	during	B
23	amino	B
24	acid	B
25	starvation	B
26	.	B

1	In	B
2	Saccharomyces	B
3	cerevisiae	B
4	,	B
5	entry	B
6	into	B
7	mitosis	B
8	requires	B
9	activation	B
10	of	B
11	the	B
12	cyclin	B
13	-	B
14	dependent	B
15	kinase	B
16	Cdc28	B
17	in	B
18	its	B
19	cyclin	B
20	B	B
21	(	B
22	Clb	B
23	)-	B
24	associated	B
25	form	B
26	.	B

1	Data	B
2	from	B
3	in	B
4	vitro	B
5	splicing	B
6	assays	B
7	,	B
8	UV	B
9	crosslinking	B
10	and	B
11	RNA	B
12	-	B
13	binding	B
14	competition	B
15	experiments	B
16	indicates	B
17	a	B
18	strong	B
19	correlation	B
20	between	B
21	the	B
22	binding	B
23	affinities	B
24	of	B
25	PSI	B
26	for	B
27	the	B
28	SELEX	B
29	sequences	B
30	and	B
31	their	B
32	ability	B
33	to	B
34	modulate	B
35	splicing	B
36	of	B
37	P	B
38	element	B
39	IVS3	B
40	in	B
41	vitro	B
42	.	B

1	The	B
2	sensitivity	B
3	of	B
4	human	B
5	neuroblastoma	B
6	cells	B
7	SK	B
8	-	B
9	N	B
10	-	B
11	SH	B
12	to	B
13	undergo	B
14	apoptosis	B
15	induced	B
16	by	B
17	thapsigargin	B
18	was	B
19	examined	B
20	.	B

1	A	B
2	.,	B
3	Slatkin	B
4	,	B
5	D	B
6	.	B

1	Multiparous	B
2	women	B
3	presented	B
4	higher	B
5	BMI	B
6	(	B
7	P	B
8	=	B
9	0	B
10	.	B
11	01	B
12	)	B
13	and	B
14	PBF	B
15	(	B
16	P	B
17	=	B
18	0	B
19	.	B
20	03	B
21	)	B
22	compared	B
23	with	B
24	primi	B
25	-	B
26	and	B
27	nulliparous	B
28	groups	B
29	.	B

1	CONCLUSIONS	B
2	AND	B
3	CLINICAL	B
4	RELEVANCE	B
5	:	B
6	Increased	B
7	cortical	B
8	thickness	B
9	and	B
10	geometric	B
11	properties	B
12	of	B
13	left	B
14	MCB	B
15	-	B
16	IV	B
17	and	B
18	-	B
19	V	B
20	of	B
21	Greyhounds	B
22	,	B
23	together	B
24	with	B
25	altered	B
26	turnover	B
27	and	B
28	orientation	B
29	of	B
30	osteons	B
31	in	B
32	the	B
33	dorsal	B
34	quadrants	B
35	of	B
36	left	B
37	MCB	B
38	,	B
39	are	B
40	site	B
41	-	B
42	specific	B
43	adaptive	B
44	responses	B
45	associated	B
46	with	B
47	asymmetric	B
48	cyclic	B
49	loading	B
50	as	B
51	a	B
52	result	B
53	of	B
54	racing	B
55	on	B
56	circular	B
57	tracks	B
58	.	B

1	To	B
2	examine	B
3	transcriptional	B
4	regulation	B
5	of	B
6	the	B
7	rat	B
8	eIF4E	B
9	gene	B
10	,	B
11	2	B
12	.	B
13	1	B
14	kB	B
15	of	B
16	the	B
17	rat	B
18	eIF4E	B
19	promoter	B
20	region	B
21	was	B
22	cloned	B
23	and	B
24	the	B
25	contribution	B
26	of	B
27	specific	B
28	elements	B
29	in	B
30	regulating	B
31	transcription	B
32	was	B
33	determined	B
34	in	B
35	primary	B
36	cultures	B
37	of	B
38	rat	B
39	cardiocytes	B
40	and	B
41	in	B
42	a	B
43	murine	B
44	C	B
45	(	B
46	2	B
47	)	B
48	C	B
49	(	B
50	12	B
51	)	B
52	myoblast	B
53	cell	B
54	line	B
55	.	B

1	The	B
2	prevalence	B
3	of	B
4	tobacco	B
5	dependence	B
6	diagnosed	B
7	according	B
8	to	B
9	the	B
10	ICD	B
11	-	B
12	10	B
13	criteria	B
14	was	B
15	higher	B
16	in	B
17	alcohol	B
18	-	B
19	dependent	B
20	individuals	B
21	(	B
22	58	B
23	.	B
24	1	B
25	%)	B
26	than	B
27	in	B
28	nondrinkers	B
29	or	B
30	social	B
31	drinkers	B
32	(	B
33	12	B
34	.	B
35	8	B
36	%).	B

1	Management	B
2	of	B
3	postvitrectomy	B
4	diabetic	B
5	vitreous	B
6	hemorrhage	B
7	with	B
8	tissue	B
9	plasminogen	B
10	activator	B
11	(	B
12	t	B
13	-	B
14	PA	B
15	)	B
16	and	B
17	volume	B
18	homeostatic	B
19	fluid	B
20	-	B
21	fluid	B
22	exchanger	B
23	.	B

1	Transactivation	B
2	of	B
3	oIFNtau	B
4	enhancer	B
5	-	B
6	reporter	B
7	constructs	B
8	was	B
9	primarily	B
10	regulated	B
11	by	B
12	three	B
13	regions	B
14	containing	B
15	AP	B
16	-	B
17	1	B
18	site	B
19	,	B
20	GATA	B
21	like	B
22	sequence	B
23	and	B
24	site	B
25	(	B
26	s	B
27	)	B
28	unidentified	B
29	.	B

1	SELECTION	B
2	CRITERIA	B
3	:	B
4	Randomised	B
5	controlled	B
6	trials	B
7	of	B
8	cabergoline	B
9	versus	B
10	placebo	B
11	in	B
12	patients	B
13	with	B
14	a	B
15	clinical	B
16	diagnosis	B
17	of	B
18	idiopathic	B
19	Parkinson	B
20	'	B
21	s	B
22	disease	B
23	and	B
24	long	B
25	-	B
26	term	B
27	complications	B
28	of	B
29	levodopa	B
30	therapy	B
31	.	B

1	0	B
2	%)	B
3	and	B
4	IL	B
5	-	B
6	12	B
7	(	B
8	42	B
9	.	B
10	6	B
11	%	B
12	vs	B
13	.	B

1	Copyright	B
2	2000	B
3	John	B
4	Wiley	B
5	&	B
6	Sons	B
7	,	B
8	Ltd	B
9	.	B

1	Here	B
2	we	B
3	demonstrate	B
4	that	B
5	native	B
6	MRCK	B
7	exists	B
8	in	B
9	high	B
10	-	B
11	molecular	B
12	-	B
13	weight	B
14	complexes	B
15	.	B

1	METHODS	B
2	:	B
3	This	B
4	retrospective	B
5	review	B
6	comprised	B
7	2711	B
8	eyes	B
9	that	B
10	had	B
11	LASIK	B
12	between	B
13	September	B
14	1996	B
15	and	B
16	September	B
17	1999	B
18	.	B

1	Sixty	B
2	-	B
3	one	B
4	cases	B
5	of	B
6	cholera	B
7	,	B
8	all	B
9	caused	B
10	by	B
11	V	B
12	.	B
13	cholerae	B
14	O1	B
15	,	B
16	were	B
17	reported	B
18	.	B

1	This	B
2	could	B
3	lead	B
4	to	B
5	subsequent	B
6	outbreaks	B
7	if	B
8	Babesia	B
9	carrier	B
10	animals	B
11	were	B
12	to	B
13	be	B
14	introduced	B
15	into	B
16	the	B
17	herd	B
18	.	B

1	Instead	B
2	,	B
3	TRPS1	B
4	potently	B
5	and	B
6	specifically	B
7	represses	B
8	transcriptional	B
9	activation	B
10	mediated	B
11	by	B
12	other	B
13	GATA	B
14	factors	B
15	.	B

1	Eliminating	B
2	any	B
3	subset	B
4	of	B
5	ASCUS	B
6	reduces	B
7	the	B
8	ASCUS	B
9	/	B
10	SIL	B
11	ratio	B
12	but	B
13	also	B
14	significantly	B
15	diminishes	B
16	the	B
17	sensitivity	B
18	of	B
19	the	B
20	Papanicolaou	B
21	test	B
22	.	B

1	In	B
2	order	B
3	to	B
4	overcome	B
5	the	B
6	false	B
7	positive	B
8	readings	B
9	that	B
10	are	B
11	possible	B
12	in	B
13	sphincter	B
14	manometry	B
15	,	B
16	we	B
17	proposed	B
18	to	B
19	use	B
20	secretin	B
21	stimulated	B
22	endoscopic	B
23	ultrasound	B
24	(	B
25	SSEUS	B
26	)	B
27	to	B
28	measure	B
29	pancreatic	B
30	ductal	B
31	response	B
32	as	B
33	an	B
34	adjunctive	B
35	method	B
36	to	B
37	aid	B
38	and	B
39	supplement	B
40	the	B
41	diagnosis	B
42	.	B

1	Endovascular	B
2	aneurysm	B
3	repair	B
4	with	B
5	the	B
6	AneuRx	B
7	stent	B
8	-	B
9	graft	B
10	is	B
11	safe	B
12	,	B
13	but	B
14	is	B
15	it	B
16	effective	B
17	?	B

1	The	B
2	difference	B
3	of	B
4	hardness	B
5	over	B
6	time	B
7	of	B
8	composite	B
9	specimens	B
10	was	B
11	measured	B
12	using	B
13	Knoop	B
14	hardness	B
15	measurements	B
16	taken	B
17	at	B
18	the	B
19	top	B
20	and	B
21	bottom	B
22	surfaces	B
23	of	B
24	resin	B
25	specimens	B
26	made	B
27	in	B
28	a	B
29	Teflon	B
30	mold	B
31	the	B
32	same	B
33	dimensions	B
34	as	B
35	the	B
36	cavity	B
37	prepared	B
38	in	B
39	dentin	B
40	.	B

1	Implications	B
2	in	B
3	biomonitoring	B
4	of	B
5	the	B
6	observed	B
7	accumulation	B
8	patterns	B
9	,	B
10	especially	B
11	in	B
12	the	B
13	different	B
14	tissues	B
15	of	B
16	Posidonia	B
17	oceanica	B
18	,	B
19	are	B
20	discussed	B
21	.	B

1	Based	B
2	on	B
3	mutational	B
4	data	B
5	and	B
6	possible	B
7	mRNA	B
8	structure	B
9	,	B
10	we	B
11	hypothesized	B
12	about	B
13	the	B
14	effect	B
15	of	B
16	mRNA	B
17	structure	B
18	on	B
19	translation	B
20	of	B
21	the	B
22	two	B
23	major	B
24	C	B
25	/	B
26	EBPepsilon	B
27	isoforms	B
28	:	B
29	p32	B
30	and	B
31	p30	B
32	.	B

1	Retinoids	B
2	participate	B
3	in	B
4	the	B
5	onset	B
6	of	B
7	differentiation	B
8	,	B
9	apoptosis	B
10	and	B
11	the	B
12	inhibition	B
13	of	B
14	growth	B
15	in	B
16	a	B
17	wide	B
18	variety	B
19	of	B
20	normal	B
21	and	B
22	cancerous	B
23	cells	B
24	.	B

1	We	B
2	conclude	B
3	that	B
4	RPMS	B
5	acts	B
6	as	B
7	a	B
8	negative	B
9	regulator	B
10	of	B
11	EBNA2	B
12	and	B
13	Notch	B
14	activity	B
15	through	B
16	its	B
17	interactions	B
18	with	B
19	the	B
20	CBF1	B
21	-	B
22	associated	B
23	corepressor	B
24	complex	B
25	.	B

1	Isolated	B
2	Systolic	B
3	Hypertension	B
4	:	B
5	An	B
6	Update	B
7	.	B

1	Transfection	B
2	of	B
3	EGFP	B
4	-	B
5	tagged	B
6	DENTT	B
7	NLS	B
8	deletion	B
9	constructs	B
10	lacking	B
11	the	B
12	bipartite	B
13	NLS	B
14	-	B
15	1	B
16	were	B
17	excluded	B
18	from	B
19	the	B
20	nucleolus	B
21	.	B

1	VE	B
2	-	B
3	DEF	B
4	animals	B
5	had	B
6	significantly	B
7	higher	B
8	(	B
9	p	B
10	<	B
11	0	B
12	.	B
13	05	B
14	)	B
15	levels	B
16	of	B
17	myocardial	B
18	lipid	B
19	peroxidation	B
20	and	B
21	lower	B
22	(	B
23	p	B
24	<	B
25	0	B
26	.	B
27	05	B
28	)	B
29	protein	B
30	thiols	B
31	following	B
32	I	B
33	-	B
34	R	B
35	compared	B
36	to	B
37	the	B
38	CON	B
39	animals	B
40	.	B

1	The	B
2	position	B
3	of	B
4	the	B
5	analyst	B
6	as	B
7	expert	B
8	:	B
9	yesterday	B
10	and	B
11	today	B
12	.	B

1	Furthermore	B
2	,	B
3	we	B
4	showed	B
5	that	B
6	ERSF	B
7	including	B
8	NF	B
9	-	B
10	Y	B
11	and	B
12	ATF6alpha	B
13	and	B
14	/	B
15	or	B
16	beta	B
17	and	B
18	capable	B
19	of	B
20	binding	B
21	to	B
22	ERSE	B
23	is	B
24	indeed	B
25	formed	B
26	when	B
27	the	B
28	cellular	B
29	UPR	B
30	is	B
31	activated	B
32	.	B

1	We	B
2	performed	B
3	the	B
4	present	B
5	study	B
6	to	B
7	clarify	B
8	the	B
9	relationship	B
10	between	B
11	the	B
12	DOX	B
13	binding	B
14	ability	B
15	(%	B
16	DB	B
17	)	B
18	and	B
19	the	B
20	histologic	B
21	response	B
22	,	B
23	rate	B
24	of	B
25	decrease	B
26	in	B
27	tumor	B
28	volume	B
29	of	B
30	malignant	B
31	soft	B
32	tissue	B
33	tumors	B
34	after	B
35	preoperative	B
36	chemotherapy	B
37	and	B
38	prognosis	B
39	.	B

1	We	B
2	have	B
3	also	B
4	isolated	B
5	and	B
6	analyzed	B
7	the	B
8	5	B
9	'	B
10	flanking	B
11	region	B
12	of	B
13	the	B
14	pea	B
15	33RNP	B
16	gene	B
17	.	B

1	We	B
2	have	B
3	previously	B
4	shown	B
5	that	B
6	the	B
7	adenoviral	B
8	12S	B
9	E1A	B
10	protein	B
11	modulates	B
12	the	B
13	phosphorylation	B
14	status	B
15	of	B
16	p130	B
17	and	B
18	p107	B
19	without	B
20	apparent	B
21	changes	B
22	in	B
23	the	B
24	cell	B
25	cycle	B
26	dependent	B
27	phosphorylation	B
28	of	B
29	the	B
30	retinoblastoma	B
31	protein	B
32	.	B

1	Baseline	B
2	MBF	B
3	in	B
4	females	B
5	was	B
6	significantly	B
7	(	B
8	P	B
9	<	B
10	0	B
11	.	B
12	001	B
13	)	B
14	higher	B
15	than	B
16	in	B
17	males	B
18	.	B

1	Only	B
2	nine	B
3	patients	B
4	were	B
5	offered	B
6	surgery	B
7	(	B
8	six	B
9	were	B
10	resected	B
11	and	B
12	three	B
13	were	B
14	found	B
15	inoperable	B
16	).	B

1	The	B
2	deubiquitinating	B
3	enzyme	B
4	DUB	B
5	-	B
6	2	B
7	is	B
8	induced	B
9	in	B
10	response	B
11	to	B
12	IL	B
13	-	B
14	2	B
15	but	B
16	as	B
17	yet	B
18	its	B
19	function	B
20	has	B
21	not	B
22	been	B
23	determined	B
24	.	B

1	A	B
2	split	B
3	motor	B
4	domain	B
5	in	B
6	a	B
7	cytoplasmic	B
8	dynein	B
9	.	B

1	Immunological	B
2	and	B
3	biochemical	B
4	characterization	B
5	of	B
6	streptococcal	B
7	pyrogenic	B
8	exotoxins	B
9	I	B
10	and	B
11	J	B
12	(	B
13	SPE	B
14	-	B
15	I	B
16	and	B
17	SPE	B
18	-	B
19	J	B
20	)	B
21	from	B
22	Streptococcus	B
23	pyogenes	B
24	.	B

1	Five	B
2	modalities	B
3	of	B
4	nonpharmacologic	B
5	approaches	B
6	are	B
7	recommended	B
8	at	B
9	present	B
10	for	B
11	lifestyle	B
12	modification	B
13	and	B
14	control	B
15	of	B
16	arterial	B
17	blood	B
18	pressure	B
19	elevation	B
20	:	B
21	1	B
22	)	B
23	weight	B
24	reduction	B
25	to	B
26	ideal	B
27	body	B
28	weight	B
29	,	B
30	since	B
31	it	B
32	reduces	B
33	risk	B
34	of	B
35	hypertension	B
36	as	B
37	well	B
38	as	B
39	overall	B
40	cardiovascular	B
41	morbidity	B
42	and	B
43	mortality	B
44	;	B
45	2	B
46	)	B
47	dietary	B
48	sodium	B
49	restriction	B
50	to	B
51	less	B
52	than	B
53	2	B
54	g	B
55	a	B
56	day	B
57	,	B
58	without	B
59	assurance	B
60	that	B
61	it	B
62	will	B
63	normalize	B
64	arterial	B
65	pressure	B
66	although	B
67	it	B
68	may	B
69	help	B
70	reduce	B
71	dosage	B
72	and	B
73	numbers	B
74	of	B
75	prescribed	B
76	antihypertensive	B
77	drugs	B
78	;	B
79	3	B
80	)	B
81	moderation	B
82	of	B
83	alcohol	B
84	consumption	B
85	to	B
86	less	B
87	than	B
88	1	B
89	ounce	B
90	a	B
91	day	B
92	;	B
93	4	B
94	)	B
95	a	B
96	regular	B
97	isotonic	B
98	exercise	B
99	program	B
100	;	B
101	and	B
102	5	B
103	)	B
104	cessation	B
105	of	B
106	tobacco	B
107	consumption	B
108	.	B

1	Descriptions	B
2	of	B
3	this	B
4	locus	B
5	would	B
6	allow	B
7	comparison	B
8	with	B
9	functionally	B
10	relevant	B
11	molecular	B
12	genetic	B
13	features	B
14	of	B
15	other	B
16	species	B
17	'	B
18	homologous	B
19	loci	B
20	including	B
21	the	B
22	single	B
23	-	B
24	copy	B
25	equid	B
26	LH	B
27	/	B
28	CGbeta	B
29	gene	B
30	and	B
31	the	B
32	primate	B
33	LHbeta	B
34	-	B
35	CGbeta	B
36	gene	B
37	cluster	B
38	locus	B
39	.	B

1	METHODS	B
2	:	B
3	One	B
4	hundred	B
5	fourteen	B
6	consecutive	B
7	patients	B
8	(	B
9	mean	B
10	age	B
11	61	B
12	years	B
13	)	B
14	with	B
15	focal	B
16	pancreatic	B
17	masses	B
18	,	B
19	detected	B
20	on	B
21	CT	B
22	,	B
23	underwent	B
24	EUS	B
25	-	B
26	FNA	B
27	by	B
28	using	B
29	a	B
30	linear	B
31	-	B
32	array	B
33	echoendoscope	B
34	and	B
35	22	B
36	-	B
37	gauge	B
38	needles	B
39	.	B

1	The	B
2	effects	B
3	of	B
4	chlordiazepoxide	B
5	(	B
6	2	B
7	.	B
8	5	B
9	-	B
10	15	B
11	.	B
12	0mg	B
13	/	B
14	kg	B
15	),	B
16	a	B
17	full	B
18	benzodiazepine	B
19	receptor	B
20	agonist	B
21	,	B
22	and	B
23	bretazenil	B
24	(	B
25	5	B
26	.	B
27	0	B
28	-	B
29	30	B
30	.	B
31	0mg	B
32	/	B
33	kg	B
34	),	B
35	a	B
36	partial	B
37	benzodiazepine	B
38	receptor	B
39	agonist	B
40	,	B
41	were	B
42	examined	B
43	in	B
44	the	B
45	murine	B
46	elevated	B
47	plus	B
48	-	B
49	maze	B
50	paradigm	B
51	.	B

1	Acute	B
2	effects	B
3	of	B
4	LI	B
5	160	B
6	(	B
7	extract	B
8	of	B
9	Hypericum	B
10	perforatum	B
11	,	B
12	St	B
13	John	B
14	'	B
15	s	B
16	wort	B
17	)	B
18	and	B
19	two	B
20	of	B
21	its	B
22	constituents	B
23	on	B
24	neuroendocrine	B
25	responses	B
26	in	B
27	the	B
28	rat	B
29	.	B

1	Guidelines	B
2	for	B
3	performing	B
4	a	B
5	routine	B
6	spiral	B
7	assay	B
8	are	B
9	presented	B
10	,	B
11	and	B
12	alternative	B
13	test	B
14	methods	B
15	intended	B
16	to	B
17	overcome	B
18	a	B
19	variety	B
20	of	B
21	technical	B
22	difficulties	B
23	(	B
24	such	B
25	as	B
26	restricted	B
27	sample	B
28	availability	B
29	,	B
30	sample	B
31	viscosity	B
32	or	B
33	volatility	B
34	,	B
35	etc	B
36	.)	B
37	are	B
38	recommended	B
39	.	B

1	An	B
2	additional	B
3	9	B
4	patients	B
5	achieved	B
6	normal	B
7	levels	B
8	with	B
9	adjunctive	B
10	drug	B
11	therapy	B
12	.	B

1	Anti	B
2	-	B
3	nucleolin	B
4	mAb	B
5	was	B
6	used	B
7	to	B
8	confirm	B
9	the	B
10	antigenic	B
11	properties	B
12	of	B
13	this	B
14	p95	B
15	component	B
16	.	B

1	Eliminating	B
2	any	B
3	subset	B
4	of	B
5	ASCUS	B
6	reduces	B
7	the	B
8	ASCUS	B
9	/	B
10	SIL	B
11	ratio	B
12	but	B
13	also	B
14	significantly	B
15	diminishes	B
16	the	B
17	sensitivity	B
18	of	B
19	the	B
20	Papanicolaou	B
21	test	B
22	.	B

1	Prrp	B
2	can	B
3	also	B
4	associate	B
5	with	B
6	the	B
7	EVH1	B
8	domain	B
9	of	B
10	Mena	B
11	,	B
12	another	B
13	microfilament	B
14	-	B
15	associated	B
16	protein	B
17	.	B

1	Experience	B
2	with	B
3	xylene	B
4	-	B
5	free	B
6	sections	B
7	since	B
8	1995	B
9	at	B
10	the	B
11	Vrinnevi	B
12	Hospital	B
13	is	B
14	favorable	B
15	.	B

1	Acquired	B
2	antithrombin	B
3	deficiency	B
4	in	B
5	sepsis	B
6	.	B

1	SIP1	B
2	(	B
3	Smad	B
4	interacting	B
5	protein	B
6	1	B
7	)	B
8	and	B
9	deltaEF1	B
10	(	B
11	delta	B
12	-	B
13	crystallin	B
14	enhancer	B
15	binding	B
16	factor	B
17	)	B
18	are	B
19	structurally	B
20	similar	B
21	transcriptional	B
22	repressors	B
23	.	B

1	SERS	B
2	spectra	B
3	were	B
4	obtained	B
5	by	B
6	vacuum	B
7	evaporation	B
8	and	B
9	casting	B
10	of	B
11	p	B
12	-	B
13	NTP	B
14	onto	B
15	silver	B
16	island	B
17	films	B
18	,	B
19	and	B
20	also	B
21	from	B
22	colloidal	B
23	silver	B
24	solutions	B
25	.	B

1	The	B
2	moduli	B
3	of	B
4	elasticity	B
5	of	B
6	the	B
7	gray	B
8	and	B
9	white	B
10	matter	B
11	were	B
12	3	B
13	.	B
14	4	B
15	+/-	B
16	1	B
17	.	B
18	4	B
19	kPa	B
20	(	B
21	mean	B
22	+/-	B
23	standard	B
24	deviation	B
25	)	B
26	and	B
27	3	B
28	.	B
29	4	B
30	+/-	B
31	0	B
32	.	B
33	9	B
34	kPa	B
35	in	B
36	the	B
37	axial	B
38	section	B
39	,	B
40	3	B
41	+/-	B
42	0	B
43	.	B
44	3	B
45	kPa	B
46	and	B
47	3	B
48	.	B
49	5	B
50	+/-	B
51	0	B
52	.	B
53	5	B
54	kPa	B
55	in	B
56	the	B
57	frontal	B
58	section	B
59	,	B
60	and	B
61	3	B
62	.	B
63	5	B
64	+/-	B
65	0	B
66	.	B
67	9	B
68	kPa	B
69	and	B
70	2	B
71	.	B
72	8	B
73	+/-	B
74	0	B
75	.	B
76	4	B
77	kPa	B
78	in	B
79	the	B
80	sagittal	B
81	section	B
82	,	B
83	respectively	B
84	.	B

1	[	B
2	Clinical	B
3	and	B
4	epidemiological	B
5	characteristics	B
6	of	B
7	squamous	B
8	cell	B
9	carcinoma	B
10	of	B
11	the	B
12	oral	B
13	cavity	B
14	in	B
15	women	B
16	]	B
17	BACKGROUND	B
18	:	B
19	Squamous	B
20	cell	B
21	carcinoma	B
22	(	B
23	SCC	B
24	)	B
25	of	B
26	the	B
27	oral	B
28	cavity	B
29	occurs	B
30	mainly	B
31	in	B
32	the	B
33	male	B
34	population	B
35	.	B

1	The	B
2	core	B
3	promoter	B
4	of	B
5	human	B
6	thioredoxin	B
7	reductase	B
8	1	B
9	:	B
10	cloning	B
11	,	B
12	transcriptional	B
13	activity	B
14	,	B
15	and	B
16	Oct	B
17	-	B
18	1	B
19	,	B
20	Sp1	B
21	,	B
22	and	B
23	Sp3	B
24	binding	B
25	reveal	B
26	a	B
27	housekeeping	B
28	-	B
29	type	B
30	promoter	B
31	for	B
32	the	B
33	AU	B
34	-	B
35	rich	B
36	element	B
37	-	B
38	regulated	B
39	gene	B
40	.	B

1	Phase	B
2	II	B
3	trial	B
4	of	B
5	the	B
6	anti	B
7	-	B
8	G	B
9	(	B
10	D2	B
11	)	B
12	monoclonal	B
13	antibody	B
14	3F8	B
15	and	B
16	granulocyte	B
17	-	B
18	macrophage	B
19	colony	B
20	-	B
21	stimulating	B
22	factor	B
23	for	B
24	neuroblastoma	B
25	.	B

1	A	B
2	log	B
3	-	B
4	linear	B
5	dose	B
6	-	B
7	response	B
8	was	B
9	obtained	B
10	for	B
11	the	B
12	average	B
13	increase	B
14	in	B
15	FEV1	B
16	up	B
17	to	B
18	6	B
19	h	B
20	(	B
21	AUC0	B
22	-	B
23	6	B
24	h	B
25	)	B
26	and	B
27	peak	B
28	FEV1	B
29	across	B
30	the	B
31	dose	B
32	range	B
33	administered	B
34	by	B
35	Respimat	B
36	.	B

1	Plasma	B
2	DHE	B
3	concentration	B
4	rose	B
5	promptly	B
6	above	B
7	5	B
8	ng	B
9	/	B
10	ml	B
11	after	B
12	the	B
13	application	B
14	of	B
15	the	B
16	PSA	B
17	tape	B
18	onto	B
19	the	B
20	damaged	B
21	skin	B
22	in	B
23	hairless	B
24	rat	B
25	.	B

1	A	B
2	complete	B
3	drug	B
4	history	B
5	was	B
6	compiled	B
7	,	B
8	specifying	B
9	the	B
10	amount	B
11	and	B
12	duration	B
13	of	B
14	VGB	B
15	medication	B
16	.	B

1	Epithelial	B
2	cytotoxicity	B
3	of	B
4	combined	B
5	antibiotics	B
6	was	B
7	additive	B
8	,	B
9	with	B
10	no	B
11	evidence	B
12	of	B
13	competition	B
14	or	B
15	synergism	B
16	.	B

1	In	B
2	Cd	B
3	-	B
4	spiked	B
5	OECD	B
6	soil	B
7	,	B
8	internal	B
9	Cd	B
10	levels	B
11	were	B
12	linearly	B
13	related	B
14	to	B
15	external	B
16	Cd	B
17	concentrations	B
18	,	B
19	whereas	B
20	the	B
21	springtails	B
22	maintained	B
23	fixed	B
24	internal	B
25	levels	B
26	of	B
27	Cu	B
28	and	B
29	Zn	B
30	regardless	B
31	of	B
32	spiked	B
33	concentrations	B
34	.	B

1	Interestingly	B
2	,	B
3	the	B
4	similarities	B
5	with	B
6	the	B
7	endophilin	B
8	proteins	B
9	cover	B
10	the	B
11	entire	B
12	sequence	B
13	of	B
14	the	B
15	SH3GLB	B
16	family	B
17	,	B
18	suggesting	B
19	a	B
20	common	B
21	fold	B
22	and	B
23	presumably	B
24	a	B
25	common	B
26	mode	B
27	of	B
28	action	B
29	.	B

1	Reovirus	B
2	mRNAs	B
3	are	B
4	efficiently	B
5	translated	B
6	within	B
7	host	B
8	cells	B
9	despite	B
10	the	B
11	absence	B
12	of	B
13	3	B
14	'	B
15	polyadenylated	B
16	tails	B
17	.	B

1	Grippers	B
2	with	B
3	integrated	B
4	piezoresistive	B
5	force	B
6	sensors	B
7	and	B
8	with	B
9	attached	B
10	strain	B
11	gauges	B
12	have	B
13	been	B
14	reported	B
15	.	B

1	Both	B
2	Z	B
3	and	B
4	R	B
5	expression	B
6	resulted	B
7	in	B
8	PML	B
9	dispersion	B
10	in	B
11	EBV	B
12	-	B
13	positive	B
14	cells	B
15	.	B

1	The	B
2	small	B
3	copepod	B
4	Pseudonychocamptus	B
5	proximus	B
6	progressively	B
7	replaced	B
8	the	B
9	large	B
10	Tisbe	B
11	furcata	B
12	in	B
13	sand	B
14	filters	B
15	during	B
16	the	B
17	fall	B
18	of	B
19	1995	B
20	and	B
21	was	B
22	responsible	B
23	for	B
24	the	B
25	large	B
26	increase	B
27	in	B
28	meiofaunal	B
29	biomass	B
30	observed	B
31	after	B
32	spring	B
33	1996	B
34	.	B

1	Evidence	B
2	-	B
3	based	B
4	care	B
5	:	B
6	a	B
7	new	B
8	formula	B
9	for	B
10	an	B
11	old	B
12	problem	B
13	?	B

1	Nrf2	B
2	regulates	B
3	expression	B
4	of	B
5	genes	B
6	encoding	B
7	enzymes	B
8	with	B
9	antioxidant	B
10	(	B
11	e	B
12	.	B
13	g	B
14	.	B
15	heme	B
16	oxygenase	B
17	-	B
18	1	B
19	(	B
20	HO	B
21	-	B
22	1	B
23	))	B
24	or	B
25	xenobiotic	B
26	detoxification	B
27	(	B
28	e	B
29	.	B
30	g	B
31	.	B

1	Workload	B
2	,	B
3	UAPs	B
4	,	B
5	and	B
6	you	B
7	.	B

1	RESULTS	B
2	:	B
3	At	B
4	latest	B
5	examination	B
6	,	B
7	mean	B
8	UPDRS	B
9	II	B
10	and	B
11	III	B
12	scores	B
13	had	B
14	improved	B
15	by	B
16	30	B
17	%	B
18	(	B
19	on	B
20	stimulation	B
21	,	B
22	off	B
23	therapy	B
24	)	B
25	with	B
26	mean	B
27	50	B
28	%	B
29	reduction	B
30	in	B
31	daily	B
32	off	B
33	time	B
34	.	B

1	Perfusion	B
2	technique	B
3	for	B
4	perfusion	B
5	-	B
6	assisted	B
7	direct	B
8	coronary	B
9	artery	B
10	bypass	B
11	(	B
12	PADCAB	B
13	).	B

1	Copyright	B
2	2001	B
3	Academic	B
4	Press	B
5	.	B

1	The	B
2	amount	B
3	of	B
4	drained	B
5	effusion	B
6	was	B
7	measured	B
8	,	B
9	and	B
10	fluid	B
11	was	B
12	sent	B
13	for	B
14	diagnostic	B
15	assessment	B
16	.	B
